AR127635A1 - MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF - Google Patents

MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF

Info

Publication number
AR127635A1
AR127635A1 ARP220103093A ARP220103093A AR127635A1 AR 127635 A1 AR127635 A1 AR 127635A1 AR P220103093 A ARP220103093 A AR P220103093A AR P220103093 A ARP220103093 A AR P220103093A AR 127635 A1 AR127635 A1 AR 127635A1
Authority
AR
Argentina
Prior art keywords
antigen
binding fragment
specifically binds
monoclonal antibody
disorders
Prior art date
Application number
ARP220103093A
Other languages
Spanish (es)
Inventor
Alina Valerevna Beliasnikova
Olga Leonidovna Kytmanova
Darya Olegovna Chernyshova
Mariia Aleksandrovna Shchemeleva
Anastasilia Isaevna Afremova
Dmitry Valentinovich Morozov
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021132869A external-priority patent/RU2808563C2/en
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of AR127635A1 publication Critical patent/AR127635A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a un anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a la IL-4Ra (subunidad a del receptor de interleucina-4). La invención se refiere además a ácidos nucleicos que codifican dicho anticuerpo, vectores de expresión, células huésped y métodos para producirlos, métodos para producir los anticuerpos según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades o trastornos mediados por IL-4Ra, usos de los anticuerpos o composiciones farmacéuticas de los mismos para tratar enfermedades o trastornos mediados por IL-4Ra, y usos de los anticuerpos y otros compuestos terapéuticamente activos para tratar enfermedades o trastornos mediados por IL-4Ra.The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to IL-4Ra (a subunit of the interleukin-4 receptor). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing them, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody according to the invention, pharmaceutical compositions comprising the antibody according to the invention and other therapeutically active compounds, methods of treating IL-4Ra mediated diseases or disorders, uses of the antibodies or pharmaceutical compositions thereof to treat IL-4Ra mediated diseases or disorders, and uses of the antibodies and other compounds therapeutically active to treat diseases or disorders mediated by IL-4Ra.

ARP220103093A 2021-11-11 2022-11-10 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF AR127635A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021132869A RU2808563C2 (en) 2021-11-11 MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE

Publications (1)

Publication Number Publication Date
AR127635A1 true AR127635A1 (en) 2024-02-14

Family

ID=86336553

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103093A AR127635A1 (en) 2021-11-11 2022-11-10 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF

Country Status (4)

Country Link
AR (1) AR127635A1 (en)
PY (1) PY2297487A (en)
UY (1) UY40013A (en)
WO (1) WO2023085978A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR134102A1 (en) * 2023-10-12 2025-12-03 Innovent Biologics Suzhou Co Ltd ANTI-IL-4Ra ANTIBODIES AND THEIR USES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2990420T3 (en) * 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
BRPI0416603A (en) * 2003-11-07 2007-01-30 Immunex Corp antibody that binds to the human interleukin-4 (il-4) receptor
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
RU2758092C1 (en) * 2018-02-01 2021-10-26 Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. ANTIBODY TO IL-4Rα AND APPLICATION THEREOF

Also Published As

Publication number Publication date
WO2023085978A1 (en) 2023-05-19
PY2297487A (en) 2023-07-14
UY40013A (en) 2023-05-31

Similar Documents

Publication Publication Date Title
BR112021017046A2 (en) Humanized antifolate receptor 1 chimeric antigen receptors and their uses
AR127635A1 (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF
PY24114686A (en) Monoclonal antibody or antigen-binding fragment thereof that binds specifically to TNF-like ligand 1A (TL1A), and use thereof
CO2023012549A2 (en) Monoclonal antibody or antigen-binding fragment thereof that specifically binds to gd2 (gd2 ganglioside), and use thereof
AR129553A1 (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT BINDS SPECIFICALLY TO BCMA, AND ITS USE THEREOF
AR132867A1 (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS TO AXL, AND USE THEREOF
PY2530271A (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT SPECIFICALLY BINDS TO BDCA-2, AND USE THEREOF
AR132099A1 (en) Isolated bispecific antibody that binds specifically to CD3 and tumor antigen, and its use
CL2023003854A1 (en) Isolated bispecific antibody that binds specifically to CD47 and PD-L1
CL2018002690A1 (en) Variants of the humanized antibody ban2401 that specifically binds to protofibrils with an increased serum half-life pharmaceutical compositions and uses in the treatment of Alzheimer's and other neurodegenerative diseases (divisional of application No. 53-2017).